<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647886/" ref="ordinalpos=3861&amp;ncbi_uid=5021034&amp;link_uid=PMC3647886" image-link="/pmc/articles/PMC3647886/figure/F2/" class="imagepopup">Figure 2.  From: Progranulin: An emerging target for FTLD therapies. </a></div><br /><div class="p4l_captionBody"><b>A.</b> The C-terminal end of PGRN binds to the Beta-propeller region of SORT1. Upon binding, uptake of PGRN via SORT1 traffics PGRN to the lysosome. Endocytosed SORT1 is then recycled back to the cell membrane. <b>B.</b> PGRN binding to TNFR acts as an antagonist of TNFα. TNFα binding to TNFR activates pro-inflammatory signaling to induce inflammation. PGRN blocks this signaling pathway when bound to TNFR therefore inhibiting inflammation.</div></div>